|
News Code
60638
Copied
Romanian airports to install Implant Sciences desktop explosives trace detectors
TIN news: US-based Implant Sciences has won a contract to supply its QS-B220 desktop explosives trace detectors to Romanian airports.
The QS-B220 employs Ion Mobility Spectrometry (IMS) that helps in the rapid detection and identification of traces of an array of military, commercial, and homemade explosives.
The company claims that the equipment can be deployed at a low cost due to its lower maintenance requirements in comparison to other competing systems.
Implant Sciences global sales and marketing vice-president Dr Darryl Jones said: "Implant Sciences has, in this year, doubled the number of units sold in its entire history of selling trace detectors.
"This sale to Romania is another example of smaller EU country airports following market trends set by other, larger airports."
"This sale to Romania is another example of smaller EU country airports following market trends set by other, larger airports."
The QS-B220 features a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal internal automatic calibration system.
Implant Sciences CEO Dr Bill McGann said: "Over the last several months, our QS-B220 has been recognised by some of the most high-profile airport security operators and ETD customers in the world, being selected in tenders across ten different EU countries."
Implant Sciences specialises in manufacturing explosives trace detection (ETD) and drugs trace detection systems for homeland security applications and has, to date, sold around 4,400 QS-B220 units worldwide.
Since April, Implant has sold 800 QS-B220 to various airports internationally. In July alone, it sold 50 detectors to various airports in Germany, 45 in Czech Republic, and 178 units to the three major airports in Paris. Around 95% of the major airports in France are now using QS-B220
The QS-B220 employs Ion Mobility Spectrometry (IMS) that helps in the rapid detection and identification of traces of an array of military, commercial, and homemade explosives.
The company claims that the equipment can be deployed at a low cost due to its lower maintenance requirements in comparison to other competing systems.
Implant Sciences global sales and marketing vice-president Dr Darryl Jones said: "Implant Sciences has, in this year, doubled the number of units sold in its entire history of selling trace detectors.
"This sale to Romania is another example of smaller EU country airports following market trends set by other, larger airports."
"This sale to Romania is another example of smaller EU country airports following market trends set by other, larger airports."
The QS-B220 features a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal internal automatic calibration system.
Implant Sciences CEO Dr Bill McGann said: "Over the last several months, our QS-B220 has been recognised by some of the most high-profile airport security operators and ETD customers in the world, being selected in tenders across ten different EU countries."
Implant Sciences specialises in manufacturing explosives trace detection (ETD) and drugs trace detection systems for homeland security applications and has, to date, sold around 4,400 QS-B220 units worldwide.
Since April, Implant has sold 800 QS-B220 to various airports internationally. In July alone, it sold 50 detectors to various airports in Germany, 45 in Czech Republic, and 178 units to the three major airports in Paris. Around 95% of the major airports in France are now using QS-B220